Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ECM-E is a specialized hyaluronic acid complex derived from cockscomb (chicken comb), developed by Adaptgen Pharmaceutical. It is primarily utilized as a nutraceutical or dietary supplement ingredient aimed at supporting skin hydration, elasticity, and joint health. Unlike pure high-molecular-weight hyaluronic acid, ECM-E is processed to contain a naturally occurring matrix of hyaluronic acid, hydrolyzed collagen, and other glycosaminoglycans, which is intended to enhance its oral bioavailability and physiological activity. Clinical research, including pharmacokinetic studies in healthy volunteers (such as jRCT1091220141), has focused on evaluating the absorption and blood kinetics of hyaluronic acid following oral administration of this specific complex to validate its systemic availability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ECM-E.